Related Experiment Videos
Role of interferons in the therapy of melanoma
G Castello1, V Ruocco, R A Satriano
1Clinical Immunology Service, National Cancer Institute, Naples, Italy.
Abstract:
The increased incidence of disease, the relative unresponsiveness of advanced tumour to conventional therapies, and high socioeconomic costs make the malignant melanoma an aggressive cancer. During the last decade, several new biological agents have been developed, some of which have shown significant activity in the treatment of disease. However, the impact on the management of melanoma patients is still far from being conclusive. Among biological response modifiers (BRMs), interferons (IFNs) have generated a great deal of interest and have been extensively employed, although incorrectly. IFNs have been used without a specific rationale and at antiproliferative rather than biologically active doses; no extensive laboratory monitoring has been performed. In this paper data available in the current literature are reviewed and the efficacies of the different IFNs, used alone or in combination and in various treatment regimens, are compared in order to understand what is the place of IFNs in the management of patients with metastatic melanoma. Results are encouraging but still disappointing with the most effective treatment, with an overall response rate of 28.5% (10.5% complete responses). However, these results need confirmation. In conclusion, IFN is effective in the therapy of advanced melanoma, but improved response rates are necessary before it may be suitable for general, rather than investigative, use. Alternative biotherapeutical approaches and strategies are suggested.
Insights
Interferons (IFNs) show promise for advanced melanoma treatment, but response rates are insufficient for widespread use. Further research is needed to optimize biologic response modifier therapy for metastatic melanoma patients.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Malignant melanoma is an aggressive cancer with increasing incidence and poor response to conventional therapies.
- Biological agents, including interferons (IFNs), have emerged as potential treatments for advanced melanoma.
- Current use of IFNs in melanoma lacks specific rationale and optimal dosing, necessitating a review of their efficacy.
Purpose of the Study:
- To review and compare the efficacy of different interferons (IFNs) in treating metastatic melanoma.
- To determine the optimal role of IFNs in the management of advanced melanoma patients.
- To identify areas for improvement in IFN-based biotherapy for melanoma.
Main Methods:
- Systematic review of current literature on IFN therapy for metastatic melanoma.
- Comparison of different IFN types, combinations, and treatment regimens.
- Analysis of response rates, including complete and partial responses.
Main Results:
- The most effective IFN treatments yielded an overall response rate of 28.5%, with 10.5% complete responses.
- While results are encouraging, they remain disappointing and require confirmation.
- Current IFN application often lacks appropriate dosing and laboratory monitoring.
Conclusions:
- Interferons (IFNs) demonstrate effectiveness in advanced melanoma therapy but require improved response rates for general clinical use.
- Further investigation into optimal IFN dosing and treatment strategies is warranted.
- Alternative biotherapeutic approaches may be necessary to enhance melanoma treatment outcomes.